RNA, U6 small nuclear 877, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-877P profile across patient tissues and cancer cell-line models. RNU6-877P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RNU6-877P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RNU6-877P RNA expression shows 6,085 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, HNSC, and STAD as cancer lineages where RNU6-877P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-877P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-877P survival associations across molecular data types. RNU6-877P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-877P RNA expression–survival associations across cancer types. High RNU6-877P expression shows unfavorable associations in LUSC, KIRC, MESO, SKCM and PAAD, but favorable associations in LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LUSC as the clearest survival context for RNU6-877P RNA expression.
This table summarizes RNU6-877P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-877P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-877P shows lower tumor expression in COAD and THCA and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher RNU6-877P RNA expression in tumor versus normal tissue (log2 FC = +0.166, t-test p = .022).
This table shows molecular features associated with RNU6-877P in patient tissues and cancer cell lines. In patient samples, RNU6-877P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
